# A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

> **NCT07737600** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Lepu Biopharma Co., Ltd.** · enrollment: 316 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** MRG007
- **DRUG:** 5-Fluorouracil / Leucovorin Calcium
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** PD-1/VEGF antibody
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07737600
- **Lead sponsor:** Lepu Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737600, "A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07737600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*